Bioconjugation Methods for Targeted in Situ Therapeutic Delivery
US-2020038484-A1 · Feb 6, 2020 · US
Targeted in situ therapeutic delivery of secreted factors from stem cells for treatment of damaged tissue
US12558458B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12558458-B2 |
| Application number | US-201816614205-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 18, 2018 |
| Priority date | May 18, 2017 |
| Publication date | Feb 24, 2026 |
| Grant date | Feb 24, 2026 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Compositions and methods for repairing or regenerating damaged tissue are disclosed. In particular, the invention relates to methods of delivering secreted factors from stem cells to tissues in order to immobilize and concentrate such secreted factors at or under the surface of damaged tissue to promote tissue regeneration.
First claim
Opening claim text (preview).
What is claimed is: 1 . A method of accelerating wound healing and reducing neovascularization and scar formation, in damaged tissue in a subject, the method comprising: a) collecting a bone marrow-derived mesenchymal stem cell (MSC) secretome from a mesenchymal stem cell; b) mixing the bone marrow-derived mesenchymal stem cell (MSC) secretome from the stem cell with a solution comprising at least one biocompatible polymer or biopolymer to form a mixture; wherein said at least one biocompatible polymer or biopolymer comprises a mixture of hyaluronic acid and chondroitin sulfate; and c) applying the mixture to the damaged tissue, wherein the bone marrow-derived mesenchymal stem cell (MSC) secretome from the stem cell accelerates healing at or under the surface of the damaged tissue; wherein the damaged tissue is ocular tissue, wherein the ocular tissue is corneal or stromal tissue; and wherein the bone marrow-derived MSC secretome reduces neovascularization and scar formation in the damaged tissue. 2 . The method of claim 1 , wherein said at least one biocompatible polymer or biopolymer encapsulates the bone marrow-derived MSC secretome in step b). 3 . The method of claim 1 , wherein said at least one biocompatible polymer or biopolymer is adherent to tissue. 4 . The method of claim 1 , wherein said at least one biocompatible polymer or biopolymer forms a hydrogel encapsulating the bone marrow-derived MSC secretome in step b). 5 . The method of claim 1 , wherein the subject is human. 6 . The method of claim 1 , further comprising preparing the damaged tissue prior to treating the subject by exfoliation or debridement of fibrotic or necrotic tissue. 7 . The method of claim 1 , further comprising administering one or more therapeutic agents to the subject. 8 . The method of claim 7 , wherein the one or more therapeutic agents are selected from the group consisting of an analgesic agent, an anti-inflammatory agent, and an anesthetic. 9 . The method of claim 1 , wherein step c) is repeated for multiple cycles—for a time period sufficient to effect at least a partial healing of the damaged tissue, or wherein step c) is repeated for multiple cycles—for a time period sufficient to effect a complete healing of the damaged tissue. 10 . The method of claim 1 , wherein damage to the ocular tissue is caused by a chemical burn, severe dry eye, keratoconjunctivitis sicca, Sjogren's syndrome, ocular graft-versus-host disease, ocular cicatricial pemphigoid, Stevens-Johnson syndrome, physical trauma, neurotrophic keratopathy, a recurrent corneal erosion, a corneal ulcer, exposure keratopathy, retinal disease or degeneration, or optic nerve damage or degeneration. 11 . The method of claim 4 , wherein the hydrogel molds to the contours of the ocular tissue surface.
Assignees
Inventors
Classifications
Hormones, e.g. dexamethasone · CPC title
Immunomodulating agents, i.e. cytokines, interleukins, interferons · CPC title
Growth factors · CPC title
Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)} · CPC title
containing ingredients of undetermined constitution or reaction products thereof {, e.g. transplant tissue, natural bone, extracellular matrix (isolated natural compounds, e.g. collagen A61L27/24)} · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12558458B2 cover?
- Compositions and methods for repairing or regenerating damaged tissue are disclosed. In particular, the invention relates to methods of delivering secreted factors from stem cells to tissues in order to immobilize and concentrate such secreted factors at or under the surface of damaged tissue to promote tissue regeneration.
- Who is the assignee on this patent?
- Univ Leland Stanford Junior, Us Gov Veterans Affairs, Univ Illinois, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification A61L27/52. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Feb 24 2026 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).